What CellRight Technologies does

CellRight Technologies, LLC is a US-based regenerative medicine company headquartered in Universal City, Texas, that develops and sells osteoinductive bone scaffolds and related biological tissue products to healthcare providers. The company was founded in 2011 and operates as a subsidiary of the UK-based Tissue Regenix Group plc (now Tissue Regenix Group Limited), serving hospitals, surgical centers, orthopedic surgeons, and medical institutions through a B2B enterprise field sales motion. Its core technology is proprietary regenerative osteoinductive bone scaffold processing that supports natural bone healing and tissue regeneration in surgical procedures.

The product portfolio is organized into four core categories under the Tissue Regenix Group umbrella: Musculoskeletal (including osteoinductive bone scaffolds for orthopedic applications), Dermis, Soft Tissue, and Birth Tissue. Revenue is generated primarily through one-time medical device sales of these regenerative tissue products to healthcare institutions, with pricing not publicly disclosed and contracts typically structured per institutional agreement. The company delivers products through sterile supply chain channels appropriate for surgical tissue products.

The business is undergoing significant corporate restructuring. In October 2025, Jay LeCoque was appointed acting CEO and Chairman and Kirsten Lund as CFO, alongside cost reduction initiatives and a new commercial strategy. Effective January 7, 2026, the parent company delisted from the London Stock Exchange AIM market, was renamed Tissue Regenix Group Limited, and secured private equity funding from Harwood Capital. The CellRight Technologies brand is being phased out in the US over six months as operations consolidate under the Tissue Regenix Group name.

Name

CellRight Technologies

Legal name

CellRight Technologies, LLC

Website

https://cellrighttechnologies.com

Company type

Private

Founded year

2011

Operating status

Operating

Short description

CellRight Technologies is a US-based regenerative medicine subsidiary of Tissue Regenix Group that develops and sells osteoinductive bone scaffolds and related biological tissue products to hospitals, surgical centers, and orthopedic surgeons across musculoskeletal, dermis, soft tissue, and birth tissue categories.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Regenerative bone scaffolds
• Osteoinductive tissue products
• Regenerative medicine devices
• Biological bone grafts
• Soft tissue regeneration

Headquarters

HQ city

Universal City

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of regenerative tissue products including osteoinductive bone scaffolds to healthcare providers and medical institutions. Revenue generated through product sales to hospitals, surgical centers, and medical practices.

Go-to-market motion1 record

Core offering

CellRight Technologies is a regenerative medicine company that develops, manufactures, and sells osteoinductive bone scaffolds and related biological tissue products. Its portfolio covers musculoskeletal (bone) grafts, dermis, soft tissue, and birth tissue products designed to support natural bone healing and tissue regeneration in surgical and orthopedic procedures for hospitals and surgical centers.

Product overview

CellRight Technologies is a regenerative medicine company specializing in osteoinductive bone scaffolds and related tissue products. The company offers a portfolio of four core product categories under the Tissue Regenix Group umbrella: Musculoskeletal (including bone scaffolds for orthopedic applications), Dermis (skin/tissue products), Soft Tissue (soft tissue regeneration solutions), and Birth Tissue (products derived from birth tissue). These products are organized as distinct branded offerings that share the company's core regenerative technology platform. As of January 2026, the CellRight Technologies brand is being phased out and consolidated under the Tissue Regenix Group name.

Differentiator

Problem solved

Functional benefit

Products and services

• Musculoskeletal Regenerative musculoskeletal products including osteoinductive bone scaffolds for orthopedic surgical applications such as bone healing, reconstruction, and repair of complex bone defects. Targeted at hospitals, surgical centers, and orthopedic surgeons.
• Dermis Regenerative dermal (skin) tissue products derived through the company's biological tissue processing platform, used by healthcare providers for tissue repair and reconstruction procedures.
• Soft Tissue Soft tissue regeneration products for surgical repair and reconstruction procedures, sold to hospitals, surgical centers, and medical institutions performing soft tissue repair.
• Birth Tissue Regenerative products derived from birth tissue, manufactured through the company's biological tissue processing platform and sold to healthcare providers for use in surgical and tissue regeneration procedures.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Direct peers

• MiMedx: MiMedx develops and commercializes regenerative tissue products derived from birth tissue (amniotic membrane) and other allografts. It is one of the closest direct competitors to CellRight's birth tissue and musculoskeletal regenerative portfolio, serving the same hospital and surgical channels.
• Organogenesis: Organogenesis is a regenerative medicine company focused on wound care and surgical tissue products, including allograft skin and soft tissue matrices. It directly competes with CellRight's Dermis and Soft Tissue lines in surgical and wound care channels.
• MTF Biologics: MTF Biologics is a non-profit tissue processor offering musculoskeletal allografts, dermis, and soft tissue grafts. It competes with CellRight across essentially every product category — bone, dermis, soft tissue, and birth tissue — for hospital and orthopedic accounts.
• RTI Surgical: RTI Surgical (now RTI) develops allograft-based implants for spine, sports medicine, and general surgery. It is a direct competitor to CellRight's musculoskeletal bone scaffold products in orthopedic and spine surgical channels.
• LifeNet Health: LifeNet Health is a non-profit allograft tissue processor offering bone, dermis, cardiovascular, and soft tissue grafts. It competes with CellRight's musculoskeletal, dermis, and soft tissue portfolios for hospital procurement contracts.
• AlloSource: AlloSource is a non-profit tissue processor producing bone, skin, and soft tissue allografts. It is comparable to CellRight as a direct tissue allograft competitor serving orthopedic, spine, and burn/wound surgical markets.

Broad incumbents

• Integra LifeSciences: Integra LifeSciences is a large diversified medical device company with a significant regenerative tissue and wound care portfolio (Integra Dermal Regeneration Template and related products). It competes with CellRight in regenerative dermis and soft tissue but operates across many other surgical segments as well.
• Stryker: Stryker is a global medical device incumbent with deep orthopedic, spine, and surgical solutions portfolios (including Wright Medical assets). It overlaps with CellRight's musculoskeletal bone scaffold products through its orthobiologics and trauma offerings.
• Arthrex: Arthrex is a privately held orthopedic and sports medicine device leader with a regenerative and biologic product line. It is comparable to CellRight as a broad orthopedic incumbent with overlapping soft tissue and bone regenerative offerings.
• Conmed: Conmed is a diversified medical device company serving orthopedics and general surgery, including biologic and tissue products. It overlaps with CellRight in surgical tissue and orthopedic regenerative channels as a broader portfolio competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellRight Technologies